BPL-003
Archives of Psychiatry Research – December 29, 2025
Source: OpenAlex
Summary
BPL-003, a novel psychedelic compound, shows promise for treating treatment-resistant depression (TRD). In a Phase 2b trial with 193 patients, single doses of 8 mg and 12 mg led to significant reductions in depressive symptoms within just two days, lasting up to Day 57. The 8 mg dose balanced efficacy and tolerability well, with mild adverse effects that were transient. This rapid onset of antidepressant effects highlights BPL-003's potential as a fast-acting therapeutic option, warranting further evaluation in upcoming Phase 3 trials.
Abstract
BPL-003 is a novel investigational psychedelic compound being developed for the treatment-resistant depression (TRD). Its active ingredient, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), is a serotonergic psychedelic with preferential agonism at 5-HT1A receptors and rapid pharmacokinetics, allowing for a brief, supervised in-clinic administration. Preclinical studies demonstrate that 5-MeO-DMT induces robust neuroplastic effects, including increased dendritic spine formation in frontal cortical regions. Early clinical studies showed rapid onset of antidepressant effects following a single intranasal dose. In a Phase 2b randomized, controlled trial involving 193 patients with TRD, single doses of 8 mg and 12 mg BPL-003 produced rapid and statistically significant reductions in depressive symptoms as measured by the Montgomery–Åsberg Depression Rating Scale. Clinical improvement was evident as early as Day 2 and was sustained through Day 57, with the 8 mg dose demonstrating a favorable balance between efficacy and tolerability. BPL-003 was generally well tolerated, with transient and mild adverse effects that resolved within the observation period. These findings position BPL-003 as a promising fast-acting, single-dose therapeutic option for TRD and support further evaluation in Phase 3 clinical trials.